Missing links: Mechanisms of protean agonism

Molecular Pharmacology

Volumn 71, Issue 5, 2007, Pages 1200-1202

  Neubig, Richard R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 7 DIPROPYLAMINO 5,6,7,8 TETRAHYDRONAPHTHALEN 2 OL; ADENYLATE CYCLASE; ARIPIPRAZOLE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NAPHTHALENE DERIVATIVE; NORAPOMORPHINE; PERTUSSIS TOXIN; PRECLAMOL; PROPRANOLOL; PROPYLNORAPOMORPHINE; TYRAMINE; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SHORT SURVEY;

ANIMALS; GTP-BINDING PROTEIN ALPHA SUBUNIT, GI2; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; PIPERIDINES; RATS; RECEPTORS, DOPAMINE D2;

EID: 34247476171     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.034926     Document Type: Short Survey

References (25)

1. Ariens EJ (1954) Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther 99:32-49.
2. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Pineyro G (2003) Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100:11406-11411.
3. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
4. s. J Pharmacol Exp Ther 294:539-547.
5. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325.
6. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575-1584.
7. Gazi L, Nickolls SA, and Strange PG (2003) Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol 138:775-786.
8. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276:24433-24436.
9. Hjorth S, Carlsson A, Clark D, Svensson K, Wikstrom H, Sanchez D, Lindberg P, Hacksell U, Arvidsson LE, Johansson A, et al. (1983) Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology (Berl) 81:89-99.
10. Jiang M, Spicher K, Boulay G, Wang Y, and Birnbaumer L (2001) Most central nervous system D2 dopamine receptors are coupled to their effectors by Go. Proc Natl Acad Sci USA 98:3577-3582.
11. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
12. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
13. i3 Mol Pharmacol 71:1349-1359.
14. MacKinnon AC, Waters C, Jodrell D, Haslett C, and Sethi T (2001) Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. J Biol Chem 276:28083-28091.
15. Milligan G (2003) Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64:1271-1276.
16. Ohta T, Hasebe N, Tsuji S, Izawa K, Jin YT, Kido S, Natori S, Sato M, and Kikuchi K (2004) Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol. Am J Physiol 287:H2914-H2921.
17. Perez DM and Karnik SS (2005) Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev 57:147-161.
18. 2 adrenergic receptor. J Biol Chem 281:1261-1273.
19. K+Ach, in intact cells. Proc Natl Acad Sci USA 94:7921-7926.
20. Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol 11:379-393.
21. 2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280:22165-22171.
22. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
23. 2+ channels in mouse heart. Proc Natl Acad Sci USA 94:1727-1732.
24. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, and Lefkowitz RJ (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787.
25. Werry TD, Christopoulos A, and Sexton PM (2006) Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. Curr Pharm Des 12:1683-1702.